A Long-Term Therapy Based on a Pancreatic Proenzyme Formulation
We are developing a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis, the main cause of patient death from cancer. Our lead product, PRP, is a novel, patented, formulation consisting of two proenzymes mixed in a synergetic ratio that targets solid tumors. The Company’s initial target patient populations include pancreatic, ovarian and colorectal cancers.
A New Frontier In Cancer Therapy
Watch how Propanc is pioneering a new approach to cancer therapy
How PRP Works
PRP’s anti-cancer effects blocks tumor growth and aggressive dissemination by:
Several uses for PRP in clinical situations
Early stage management of solid tumors
Long term therapy following standard treatment
Preventative measure for genetically screened at risk patients
What We Have Achieved
After extensive laboratory research and a limited amount of human testing, we have evidence that PRP:
- Reduces cancer cell growth via promotion of cell differentiation
- Enhances cell adhesion and may suppress metastasis progression
- Has no serious side effects and improves patient survival
The History of PRP
PRP is based on the original work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago, using fresh pancreatic enzyme extracts.
Through advancements in science and technology, we have discovered an opportunity to commercialize an improved version of PRP administered once daily in an outpatient setting. Our intention is to supply this treatment to markets worldwide.
Our Technology: A Unique Mode of Action
When Epithelial-Mesenchymal Transition (EMT) is activated, it causes epithelial cancer cells to become invasive and stem cell-like. PRP has the ability to reverse the conversion from an epithelial to a mesenchymal phenotype, reducing the metastatic potential of the tumor.
How Our Technology Works
Significant Market Opportunity for Cancer Treatment
According to the World Health Organization, cancer deaths are expected to increase:
View Market Need